Johnson & Johnson (JNJ) Said to Settle Risperdal Case on First Day; Shares Move Higher
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $87.89 -0.23%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +8.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +8.7%
Trade JNJ Now!
Shares of Johnson & Johnson (NYSE: JNJ) are higher Monday following headlines that it settled Risperdal case on the first day of trial.
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Yahoo!'s (YHOO) Mayer: We Won't Screw Up Tumblr!
- Apple (AAPL) Continues Higher
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
